AVLN Overview

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. The Company's pipeline is focused on treating pulmonary fibrosis. It has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. It has completed ATLAS, a Phase 1b clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. It is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit.

Wall Street analysts forecast AVLN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVLN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Avalyn Pharma Inc revenue for the last quarter amounts to -27.91M USD, increased 49.12

Avalyn Pharma Inc. EPS for the last quarter amounts to -30209000.00 USD, increased 56.66

Avalyn Pharma Inc (AVLN) has 51 emplpoyees as of June 15 2026.

Today AVLN has the market capitalization of 1.33B USD.